Table 2.

Summary of the findings of the 10 most important studies.

	Findings
1	CD3+CD20+ T cells pervade the bone marrow, thymus, and secondary lymphatic organs [24].
2	CD3+CD20+ T cells are found in the CSF of MS patients [25].
3	Anti-CD20 monoclonal antibodies selectively deplete CD20+ B and T cells, efficiently suppressing inflammatory disease activity [26].
4	CD20+ T cells, which are reduced during rituximab therapy, play a pathogenic role in MS treatment [27].
5	Monoclonal antibodies targeting CD20 reduce the number of relapses in MS [28].
6	Rituximab and ublituximab efficiently deplete the increased population of CD20-expressing T cells in MS [29].
7	There is an increased frequency of CD20+ T cells in inflammatory conditions like MS [30].
8	A strong response of the CD20 T-cell population is often observed in disease-modifying treatments [31].
9	The immunopathogenesis of MS is primarily driven by deregulated T cells [32].
10	Disease-modifying therapies for MS mitigate inflammation by suppressing the activity of peripheral lymphocytes [33].